Literature DB >> 9479583

Pathogenesis of neuroimmunologic diseases. Experimental models.

C S Constantinescu1, B Hilliard, T Fujioka, M K Bhopale, D Calida, A M Rostami.   

Abstract

Animal models of autoimmune diseases have greatly improved our current understanding of the pathogenesis of human autoimmunity and have provided the potential for therapies based on manipulation of the immune system. In our laboratory, we have investigated the immunopathogenesis of autoimmune diseases of the nervous system and muscle. We have developed immune-based approaches for the suppression of experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS), and experimental autoimmune neuritis (EAN), a model for the Guillain-Barré syndrome (GBS). These approaches included induction of peripheral tolerance, immunotoxin targeting of activated T cells, and cytokine manipulations. In addition, we identified the antigen and characterized immunopathologically an autoimmune inflammatory disease of skeletal muscle, experimental autoimmune myositis (EAM), a model for the human inflammatory muscle disease polymyositis.

Entities:  

Mesh:

Year:  1998        PMID: 9479583     DOI: 10.1007/bf02786446

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  93 in total

1.  Role of CD8+ T cells in murine experimental allergic encephalomyelitis.

Authors:  H Jiang; S I Zhang; B Pernis
Journal:  Science       Date:  1992-05-22       Impact factor: 47.728

2.  Transfer of experimental allergic neuritis with P2-reactive T-cell lines.

Authors:  A Rostami; J B Burns; M J Brown; J Rosen; B Zweiman; R P Lisak; D E Pleasure
Journal:  Cell Immunol       Date:  1985-04-01       Impact factor: 4.868

Review 3.  Characterization of complement-fixing antibodies to peripheral nerve myelin in Guillain-Barré syndrome.

Authors:  C L Koski
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

4.  Investigation of in vivo activated T cells in multiple sclerosis and inflammatory central nervous system diseases.

Authors:  D A Hafler; M E Hemler; L Christenson; J M Williams; H M Shapiro; T B Strom; J L Strominger; H L Weiner
Journal:  Clin Immunol Immunopathol       Date:  1985-11

5.  Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein.

Authors:  S Brocke; K Gijbels; M Allegretta; I Ferber; C Piercy; T Blankenstein; R Martin; U Utz; N Karin; D Mitchell; T Veromaa; A Waisman; A Gaur; P Conlon; N Ling; P J Fairchild; D C Wraith; A O'Garra; C G Fathman; L Steinman
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

6.  Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies.

Authors:  A M Emslie-Smith; K Arahata; A G Engel
Journal:  Hum Pathol       Date:  1989-03       Impact factor: 3.466

7.  Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis.

Authors:  F Mokhtarian; Y Shi; D Shirazian; L Morgante; A Miller; D Grob
Journal:  J Immunol       Date:  1994-06-15       Impact factor: 5.422

8.  A permanent rat T cell line that mediates experimental allergic neuritis in the Lewis rat in vivo.

Authors:  C Linington; S Izumo; M Suzuki; K Uyemura; R Meyermann; H Wekerle
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

9.  Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice.

Authors:  F Mokhtarian; D E McFarlin; C S Raine
Journal:  Nature       Date:  1984 May 24-30       Impact factor: 49.962

10.  Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis.

Authors:  B L McRae; C L Vanderlugt; M C Dal Canto; S D Miller
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

View more
  11 in total

1.  Gender, age, and season at immunization uniquely influence the genetic control of susceptibility to histopathological lesions and clinical signs of experimental allergic encephalomyelitis: implications for the genetics of multiple sclerosis.

Authors:  Cory Teuscher; Janice Y Bunn; Parley D Fillmore; Russell J Butterfield; James F Zachary; Elizabeth P Blankenhorn
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

2.  Oral resveratrol reduces neuronal damage in a model of multiple sclerosis.

Authors:  Kenneth S Shindler; Elvira Ventura; Mahasweta Dutt; Peter Elliott; Denise C Fitzgerald; Abdolmohamad Rostami
Journal:  J Neuroophthalmol       Date:  2010-12       Impact factor: 3.042

Review 3.  The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies.

Authors:  I E Lundberg
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

4.  Timing of corticosteroid therapy is critical to prevent retinal ganglion cell loss in experimental optic neuritis.

Authors:  Mahasweta Dutt; Philomela Tabuena; Elvira Ventura; Abdolmohamad Rostami; Kenneth S Shindler
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-05       Impact factor: 4.799

5.  The Pathogenesis of the Demyelinating Form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and Immunological Profiling of Physiological Fluids.

Authors:  Rustam H Ziganshin; Olga M Ivanova; Yakov A Lomakin; Alexey A Belogurov; Sergey I Kovalchuk; Igor V Azarkin; Georgij P Arapidi; Nikolay A Anikanov; Victoria O Shender; Mikhail A Piradov; Natalia A Suponeva; Anna A Vorobyeva; Alexander G Gabibov; Vadim T Ivanov; Vadim M Govorun
Journal:  Mol Cell Proteomics       Date:  2016-05-03       Impact factor: 5.911

6.  Optic neuritis and retinal ganglion cell loss in a chronic murine model of multiple sclerosis.

Authors:  Thomas A Quinn; Mahasweta Dutt; Kenneth S Shindler
Journal:  Front Neurol       Date:  2011-08-02       Impact factor: 4.003

Review 7.  Introduction to immunology and autoimmunity.

Authors:  D A Smith; D R Germolec
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

8.  SIRT1 activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating disease.

Authors:  Reas S Khan; Kimberly Dine; Jayasri Das Sarma; Kenneth S Shindler
Journal:  Acta Neuropathol Commun       Date:  2014-01-02       Impact factor: 7.801

9.  Color vision versus pattern visual evoked potentials in the assessment of subclinical optic pathway involvement in multiple sclerosis.

Authors:  Fatih C Gundogan; Ahmet Tas; Salih Altun; Oguzhan Oz; Uzeyir Erdem; Gungor Sobaci
Journal:  Indian J Ophthalmol       Date:  2013-03       Impact factor: 1.848

10.  Expression of RhoA by inflammatory macrophages and T cells in rat experimental autoimmune neuritis.

Authors:  Zhiren Zhang; Uwe Fauser; Hermann J Schluesener
Journal:  J Cell Mol Med       Date:  2007 Jan-Feb       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.